Meta Analysis Of Clinical Value In The Chemotherapy Of Borderline Ovarian Tumor

Background:Semimalignant tumor of ovary, which was described by Taylor in 1929, is a kind of tumor subtype whose histological character and biological behavior are between benign and malignant epithelial ovarian tumors. It can be found that there are peritoneal seeding but no interstitial infiltration in this kind of tumor by histological examination. Therefore, in 1971, it was included by ovarian tumor classification of FIGO, and became the independent clinical and pathological tumor type. In 1973, it was named ' Borderline malignant ovarian tumor' by WHO, then, in 1999, in the new WHO classification of tumor, it was named 'borderline tumor'. Because the biological behavior of this borderline ovarian tumor is obviously different from ovary cancer, the early diagnosis, expectant treatment and adjuvant chemotherapy of it are still not clear. In our study, by searching and reading many articles, we found that whether the borderline tumor in stage I needed chemotherapy or not was clear. All of the authors considered that it did not need chemotherapy in stage I, moreover, some authors even considered the chemotherapy in this stage would shorten the life span of the patients. However, up to now, whether the borderline ovarian tumor in stageⅡ-Ⅳneeds chemotherapy or not is still uncertain. Objectives:In our study, we will try to make it clear whether the chemotherapy of the borderline ovarian tumor after operation can prolong the life span of the patients or not, and provide some basis to this issue.Methods:We collected all the domestic and abroad articles about borderline ovarian tumor for clinical summary and meta analysis. The database included Pubmed, Medline, CNKI and CBM. In the library of Shandong University, we retrieved all the articles and evaluated, selected, checked and analyzed them.The inclusion criteria: The first diagnosis of borderline ovarian tumor; The tumor in StageⅡ—Ⅳ; All the patients were given the operation after diagnosis; None of other malignant tumor was found; The follow up time were more than 15 years.Data collection and analysis:The data was collected and analyzed by one operator.Results:Totally five articles and 261 patients were included. Meta analysis on the selected literature was conducted by means of Review Manager 4.2 software. During 1993 to 2007, five studies were included, the odds ratio of the final results was 1.04 and 95 % confidence interval was at 0.45-2.40. In the Funnel plot, the plots of five studies were symmetrical.Conclusions:Our study indicates that for borderline ovarian tumor in StageⅡ—Ⅳ, the chemotherapy after operation can not prolong the life span of the patients. There is no significant difference between the chemotherapy group and the non-chemotherapy group (P=0.92). However, since the data and clinical trials about borderline ovarian tumor in StageⅡ—Ⅳare still very few, our study is based on only five articles. Therefore, it still needs further study in the future.